What is Chromafora?
Headquartered in Stockholm, Sweden, Chromafora operates as a specialized provider of phosphorus chemistry and nucleic acid component synthesis. The company addresses a critical market gap by offering on-demand expertise in complex chemical processes, including nucleoside, nucleotide, and oligonucleotide synthesis. By functioning as an outsourced center of excellence, Chromafora enables small and medium-sized research entities to bypass the overhead of maintaining full-time, in-house phosphorus chemists. Their service portfolio extends to the synthesis of phosphines, phosphonates, phosphoroamidites, and phospholipids, serving as a vital partner in the development of nucleoside-based therapeutic drugs and advanced medicinal chemistry applications.
How much funding has Chromafora raised?
Chromafora has raised a total of $23.1M across 1 funding round:
Other Financing Round
$23.1M
Other Financing Round (2025): $23.1M with participation from European Investment Bank
Key Investors in Chromafora
European Investment Bank
The European Investment Bank is the lending arm of the European Union, providing long-term financing and strategic support for projects that align with European policy objectives and innovation.
What's next for Chromafora?
With the recent influx of capital, Chromafora is expected to scale its operational capacity to meet the rising global demand for specialized chemical synthesis. The strategic focus will likely shift toward expanding its laboratory infrastructure and enhancing its proprietary synthesis methodologies to support larger-scale pharmaceutical partnerships. As the company transitions into this growth phase, the focus remains on maintaining its reputation for precision and efficiency, effectively serving as an external R&D arm for global biotech firms navigating the complexities of nucleic acid chemistry.
See full Chromafora company page
